Free Newsletter
| Get the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Sign up for free today! |
Psych journal discloses financial ties
The editor in chief of Psychiatric Times, a leading psychiatric journal, has stepped forward to say the journal will disclose conflicts of interest of its editorial board to "help ensure fair and accurate reporting, as well as balanced and scientifically grounded opinion and commentary." Some board members have ties to universities and drugmakers. The Integrity in Science Watch program and The International Committee of Medical Journal Editors also weigh in on the disclosure topic.
There has been a lot of hand-wringing over inappropriate industry influence on psychiatrists, as psychiatry and pharma often work closely on clinical trials and drug education. Critics say docs need to disclose and cut down on these ties, while others say partnerships with drugmakers benefit patients, as long as researchers follow their institutions' conflict of interest rules.
- read the Pharmalot report
Related Articles:
Study: Psychiatrists choose drugs over therapy
Psych docs mull ties with drugmakers
Harvard officials to probe psychiatrists' drug payments
Psychiatrists getting largest pharma gifts
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage


